Logo image of REPL

REPLIMUNE GROUP INC (REPL) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:REPL - US76029N1063 - Common Stock

9.82 USD
+0.06 (+0.61%)
Last: 12/30/2025, 4:30:01 PM
9.85 USD
+0.03 (+0.31%)
After Hours: 12/30/2025, 4:30:01 PM
Fundamental Rating

2

REPL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. The financial health of REPL is average, but there are quite some concerns on its profitability. REPL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year REPL has reported negative net income.
In the past year REPL has reported a negative cash flow from operations.
REPL had negative earnings in each of the past 5 years.
In the past 5 years REPL always reported negative operating cash flow.
REPL Yearly Net Income VS EBIT VS OCF VS FCFREPL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of REPL (-79.58%) is worse than 67.55% of its industry peers.
REPL has a Return On Equity (-117.69%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -79.58%
ROE -117.69%
ROIC N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
REPL Yearly ROA, ROE, ROICREPL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for REPL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
REPL Yearly Profit, Operating, Gross MarginsREPL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for REPL has been increased compared to 1 year ago.
The number of shares outstanding for REPL has been increased compared to 5 years ago.
REPL has a better debt/assets ratio than last year.
REPL Yearly Shares OutstandingREPL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
REPL Yearly Total Debt VS Total AssetsREPL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

REPL has an Altman-Z score of -2.22. This is a bad value and indicates that REPL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.22, REPL perfoms like the industry average, outperforming 49.25% of the companies in the same industry.
REPL has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of REPL (0.26) is worse than 68.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z -2.22
ROIC/WACCN/A
WACCN/A
REPL Yearly LT Debt VS Equity VS FCFREPL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

REPL has a Current Ratio of 6.31. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.31, REPL is doing good in the industry, outperforming 64.91% of the companies in the same industry.
REPL has a Quick Ratio of 6.31. This indicates that REPL is financially healthy and has no problem in meeting its short term obligations.
REPL has a Quick ratio of 6.31. This is in the better half of the industry: REPL outperforms 65.85% of its industry peers.
Industry RankSector Rank
Current Ratio 6.31
Quick Ratio 6.31
REPL Yearly Current Assets VS Current LiabilitesREPL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

REPL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.44%.
EPS 1Y (TTM)-13.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

REPL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.59% yearly.
The Revenue is expected to grow by 175.20% on average over the next years. This is a very strong growth
EPS Next Y-19.28%
EPS Next 2Y15.22%
EPS Next 3Y10.12%
EPS Next 5Y16.59%
Revenue Next Year-100%
Revenue Next 2Y476.05%
Revenue Next 3Y307.89%
Revenue Next 5Y175.2%

3.3 Evolution

REPL Yearly Revenue VS EstimatesREPL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
REPL Yearly EPS VS EstimatesREPL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

REPL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year REPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
REPL Price Earnings VS Forward Price EarningsREPL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
REPL Per share dataREPL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.22%
EPS Next 3Y10.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for REPL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REPLIMUNE GROUP INC

NASDAQ:REPL (12/30/2025, 4:30:01 PM)

After market: 9.85 +0.03 (+0.31%)

9.82

+0.06 (+0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-10 2026-02-10
Inst Owners106.86%
Inst Owner Change9.1%
Ins Owners1.98%
Ins Owner Change1.5%
Market Cap770.28M
Revenue(TTM)N/A
Net Income(TTM)-309.92M
Analysts82.86
Price Target12.82 (30.55%)
Short Float %19.39%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.85%
Min EPS beat(2)-15.38%
Max EPS beat(2)-12.32%
EPS beat(4)0
Avg EPS beat(4)-12.36%
Min EPS beat(4)-15.38%
Max EPS beat(4)-6.81%
EPS beat(8)3
Avg EPS beat(8)-1.14%
EPS beat(12)5
Avg EPS beat(12)0.27%
EPS beat(16)7
Avg EPS beat(16)-0.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.52%
PT rev (3m)76%
EPS NQ rev (1m)-2.42%
EPS NQ rev (3m)-1.86%
EPS NY rev (1m)-17.66%
EPS NY rev (3m)-5.9%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.93
P/tB 2.93
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.35
OCFYN/A
SpS0
BVpS3.36
TBVpS3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.58%
ROE -117.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.68%
ROA(5y)-31.31%
ROE(3y)-49.49%
ROE(5y)-38.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 197.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.31
Quick Ratio 6.31
Altman-Z -2.22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)165.62%
Cap/Depr(5y)149.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.35%
EPS Next Y-19.28%
EPS Next 2Y15.22%
EPS Next 3Y10.12%
EPS Next 5Y16.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y476.05%
Revenue Next 3Y307.89%
Revenue Next 5Y175.2%
EBIT growth 1Y-38.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.96%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-72.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.93%
OCF growth 3YN/A
OCF growth 5YN/A

REPLIMUNE GROUP INC / REPL FAQ

What is the fundamental rating for REPL stock?

ChartMill assigns a fundamental rating of 2 / 10 to REPL.


Can you provide the valuation status for REPLIMUNE GROUP INC?

ChartMill assigns a valuation rating of 0 / 10 to REPLIMUNE GROUP INC (REPL). This can be considered as Overvalued.


What is the profitability of REPL stock?

REPLIMUNE GROUP INC (REPL) has a profitability rating of 0 / 10.


What is the expected EPS growth for REPLIMUNE GROUP INC (REPL) stock?

The Earnings per Share (EPS) of REPLIMUNE GROUP INC (REPL) is expected to decline by -19.28% in the next year.